Background. Eggerthella lenta is a anaerobic gram-positive bacilli associated with polymicrobial intraabdominal infections. Recently, E. lenta was recognized as an important cause of anaerobic bloodstream infections (BSIs) associated with high mortality. Eggerthella lenta has been reported to have high minimal inhibitory concentrations (MICs) to piperacillin-tazobactam (TZP), a broad-spectrum antibiotic with anaerobic coverage commonly used in multiple centers for empiric treatment of abdominal sepsis.
METHODS

Study Population
We conducted a retrospective population-based cohort study in the Alberta Health Services, Calgary Zone, from January 2009 through December 2015. The Calgary Zone provides medical and surgical care to the residents of Calgary and the surrounding area, covering a population of 1.6 million in Alberta, Canada. Calgary Laboratory Services (CLS) is the central regional laboratory that serves the Calgary Zone. All study participants were identified from the CLS microbiology database based on positive culture for E. lenta.
Clinical Data Collection
The Conjoint Health Research Ethics Board of the University of Calgary granted ethical approval for this study. Chart review was conducted to collect clinical data. Cases were classified as community acquired (CA) if the first positive culture was obtained <72 hours after hospital admission or ≥72 hours after discharge. Hospital-acquired (HA) infections were defined when the first positive culture was obtained ≥72 hours after hospital admission or <72 hours after discharge. A patient with HA community-onset had the same criteria as for CA infection plus any of the following: had been seen in a hospital or emergency department within 1 month; had been admitted to hospital for ≥2 days within the prior 90 days; was a resident of a long-term care facility; or was on outpatient hemodialysis. Illness severity was assessed using the Charlson comorbidity index (CCI) [17] and sepsis-related organ failure assessment (SOFA) scores [18] . Eggerthella lenta BSI was defined by the isolation of this organism from 1 or more sets of blood culture bottles. Appropriate empiric antimicrobial therapy was defined as the use of combination therapy against polymicrobial infections of intraabdominal source as outlined by Infectious Diseases Society of America (IDSA) guidelines [19] or other sources (skin and soft tissue infections [SSTI] ) where appropriate [20] . Regimens were to include coverage against gram positives, gram negatives, and anaerobes, including E. lenta, based on Clinical and Laboratory Standards Institute (CLSI) breakpoints [21] .
Microbiology Methods
All specimens were processed for aerobic and anaerobic culture according to routine microbiology practices. Fluid from sterile sites and blood samples were cultured for anaerobic organism using the BacT/Alert automated instrument (bioMérieux, Laval, Quebec). Positive bottles were subcultured to Brucella blood agar (BBA) and incubated for 4 days. Tissue and deep abscess specimens were directly inoculated onto BBA and kanamycin-vancomycin laked blood agar and incubated under anaerobic conditions. Pelvic specimens were additionally inoculated to phenylethyl alcohol agar and Bacteroides bile esculin agar.
Eggerthella lenta isolates were identified by the following phenotypic characteristics: gram-positive bacilli, nonsporulating, obligate anaerobe, catalase positive, vancomycin susceptible, colistin resistant, and hydrogen sulfide positive. Definitive identification was done using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; VITEK MS bioMérieux) and/or partial targeted sequencing of the 16S rRNA gene (performed in house on a weekly basis), depending on the availability of the technologies. For organisms isolated during or after May 2013, mass spectrometry was performed following on-plate ethanolformic acid extraction in accordance with the manufacturer's instructions using the IVD Vitek MS database, version 2.0. Prior to this, organism identity was confirmed by fast partial sequencing of the 16S rRNA gene with Microseq 500 kits and an ABI Prism 3130 sequencer (Applied Biosystems, Foster City, California). Clinical sequences were queried against the IDNS Bacteria database (Smartgene IDNS, Lausanne, Switzerland), and a multisequence alignment was also done against a reference E. lenta 16S sequence. A species-level identification was made when there was almost complete homology between the reference and isolate sequences (ie, ≥99%) with only 1 or 2 mismatches. This method was also used for organisms that had no identification or a low discrimination result by MALDI-TOF MS.
Antimicrobial susceptibility testing (AST) was performed as part of routine laboratory procedures for most isolates using the E-test or MIC gradient strips, according to the manufacturer's instructions for anaerobes (bioMérieux and Liofilchem, both US Food and Drug Administration cleared). This method is commonly used in clinical microbiology laboratories and has been found to be reliable [22, 23] . The following antibiotics were tested: penicillin, piperacillin-tazobactam, meropenem (or imipenem), vancomycin, clindamycin, and metronidazole. MIC interpretive results were routinely reported according to CLSI M100 S21 (2011) breakpoints for anaerobes. In the present study, we also compared the results to new CLSI M100-S28 (2018) update [24] and European Committee on Antimicrobial Susceptibility Testing (EUCAST) [25] breakpoints for gram-positive anaerobes.
Statistical Analyses
Categorical data were expressed as total numbers or percentages and compared using χ 2 test; continuous data were expressed as medians with interquartile ranges (IQRs) and compared using rank-sum test. A univariate analysis was conducted to determine risk factors associated with 30-day mortality. All significant variables (P ≤ .05 were then included in a logistic regression model. Results were reported as odds ratios (ORs) with 95% confidence intervals. A P value ≤ .05 was considered statistically significant for all comparisons. Analysis was performed using Stata, version 14.0 (StataCorp, College Station, Texas).
RESULTS
Patient Characteristics
From 2009 to 2015, 107 adult cases of E. lenta infections were identified; 95 (89%) were BSIs and 12 (11%) occurred at other sites (non-BSI), including 11 cases of peritonitis and 1 soft tissue infection (Table 1 ). The median patient age was 66 years, and the median CCI was 2 (IQR, 0-5). Common comorbidities included diabetes (22%) and hematologic or solid organ malignancy (22%). BSIs were more likely to occur in older patients compared to infections from other sites (median age of 67 vs 52; P = .052).
Clinical Presentation of Infections
Eggerthella lenta infections were primarily CA (74%), except for E. lenta non-BSI, which were hospital-or healthcare-associated in 50% of cases ( Table 2) . A source was identified for all nonBSIs and for 82% of BSIs, with the remainder of bacteremias having an unknown source of infection. Overall, the most common sources were gastrointestinal (72.9%) followed by SSTI (8.4%), which were mainly sacral ulcers (77.8%). Appendicitis was the most common cause of gastrointestinal infection (33.3%), and most (61%) were perforated. Diverticulitis (15%), colon cancer (11%), and intraabdominal abscesses (7%) were also common, and 44% of gastrointestinal sources were associated with a perforated viscus. Cases commonly presented with fever (69%), abdominal pain (69%), and emesis (38%). Symptoms consistent with systemic inflammatory immune response syndrome (ie, marked changes in heart rate and temperature) were found in 42.5% of cases. Altered level of consciousness was found in 26% of patients (Glasgow coma score ≤14). Investigations at the time of culture positivity revealed leukocytosis (median white blood cell count count 14.9 × 10 9 cells/mm 3 ) and a median SOFA score of 1.
Treatment
Ninety-eight patients (90%) received antimicrobials; the remaining patients were not treated with antibiotics, mostly due to palliation or unsuspected sepsis at presentation to an emergency department. Seven patients were discharged home within 24 hours with no immediate follow-up, and 2 patients (1 BSI and 1 non-BSI) received therapy, but no antibiotics were specified in the medical records. Source control of the infection was attempted in 54% of patients, including surgical procedures (84%; range, 1-20 operations), with the remainder (16%) receiving percutaneous drainage via interventional radiology. TZP was the most commonly prescribed empiric antibiotic therapy (55.6%) either alone (45.3%) or in combination with another agent (11.3%). Other regimens used for empiric anaerobic coverage included metronidazole (25%) in combination with ceftriaxone, meropenem (2%), or clindamycin (0.1%). Based on IDSA guidelines for management of intraabdominal infections as well as the established MIC for TZP according to CLSI M100-S21 (2011), 65% of patients received appropriate antibiotic therapy, of which most (56%) were empirically managed with TZP monotherapy. In each patient, up to 4 antimicrobial regimens were used for a total median duration of 12 days. 
Outcomes of E. lenta Infections
The 7-day, 30-day, and 365-day mortality was 12%, 20.6%, and 28.9%, respectively, with median follow-up of 585 days. Although 30-day mortality was higher for BSI vs non-BSI, this trend was not statistically significant (23.2% vs 0%; P = .06). Acute appendicitis without perforation had the lowest mortality (3.8%) of all gastrointestinal infections, while those infections associated with perforated viscus (ie, perforated appendicitis, necrotic bowel, colon cancer, and diverticular disease) had the highest mortality (44.7%).
Isolate Characteristics
Among BSI cases, only 1 of 95 had repeatedly positive blood cultures. The median time to positivity was 51 hours. Ultimately, 50.5% of E. lenta isolates were identified using MALDI-TOF and the remainder by partial targeted sequencing of the 16S rRNA gene. Definitive organism identification was reported an average of 7 days or 13 days after collection of specimens when E. lenta was identified using MALDI-TOF and/or 16S sequencing. Susceptibilities were reported within 9 days of specimen collection in 75% of cases but delayed in a few cases (up to 25 days).
Eggerthella lenta was part of polymicrobial infection in 40% of cases. Other anaerobes represented 60% of copathogens, the most common was B. fragilis (27.9%), followed by Clostridium spp. (13.9%) and Parvimonas micra (11.6%). Aerobic copathogens included Escherichia coli (16.3%), Pseudomonas aeruginosa (16.3%), Streptococcus anginosus (6.9%), Gemella spp. (6.9%), and Enterococcus spp. (6.9%). Three or more organisms were isolated from a large percentage of BSIs (27.3%) and non-BSIs (50%).
Susceptibility testing (Table 3) revealed 100% susceptibility to carbapenems, 99% to metronidazole, and 98% to vancomycin. However, elevated MICs to penicillin (MIC50 1 μg/mL and MIC90 2 μg/mL) and TZP (MIC50 32 μg/mL and MIC90 64 μg/ mL) were observed; this translated to 80%, 45%, and 6% susceptibility to TZP when CLSI M100-S21 (2011), CLSI M100-S28 (2018), and EUCAST breakpoints were used.
Incidence of E. lenta BSI
The local population incidence of E. lenta BSI compared to previously published cases from 2000-2008 [26] had increased from 0.27/100c000 per year in 2001-2008 to 0.84/100c000 per year in our study period from 2009 through 2015.
Risk Factors Associated With BSI 30-day Mortality
Risk factors associated with 30-day mortality in the univariate analysis included severity of acute illness, as defined by a SOFA score of 5 or higher (P < .01; Table 4 ), intensive care unit (ICU) admission (P < .01), and lack of antibiotic management (P = .03). Surprisingly, the appropriateness of empiric antimicrobial therapy based on adherence to IDSA guidelines was not associated with a difference in 30-day mortality (21.7% vs 20.8%; P = .93; Tables 4 and 5).
As 42.8% of patients with BSIs in our study were empirically treated with TZP monotherapy and up to 94% of isolates displayed high TZP MICs, we surmised that this may be a risk factor for mortality and may explain why adherence to IDSA guidelines did not influence mortality. Indeed, when we compared TZP monotherapy to other empiric regimens without regard for final susceptibility results, TZP monotherapy was associated with increased mortality (66.7% vs 36.3%; P = .02; Tables 4 and 5 ). The distribution of TZP MICs among fatal and nonfatal E. lenta BSI cases was not significantly different (P = .72; Figure 1 ), although a weak trend toward higher MICs among fatal cases was noted. Next, we analyzed the impact of antimicrobial therapy on 30-day mortality, taking into consideration various clinically used breakpoint guidelines for anaerobes with our antimicrobial susceptibility testing data. The major difference in MIC breakpoints for TZP occurs with a resistant range defined for various reported guidelines including >32 µg/mL, >16 µg/mL, and >8µg/mL for CLSI 2011, CLSI 2018, and EUCAST, respectively. When we compared those who were adequately treated with empiric antibiotics (as per IDSA guidelines), we found that appropriateness of regimens correlated with 30-day mortality only when TZP MIC breakpoints for EUCAST (appropriate vs not appropriate; P = .01) and CLSI 2018 (P = .01) were used but not CLSI 2011 (P = .19; Table 5 ). Next, we determined whether TZP monotherapy was associated with 30-day mortality by performing a subgroup analysis to compare 30-day mortality among those for whom empiric TZP monotherapy was deemed appropriate using different TZP MIC breakpoints with other appropriate antimicrobial regimens. TZP monotherapy vs other regimens was associated with increased mortality using CLSI 2011 (TZP vs other; P = .02) but not when using CLSI 2018 (P = .19) and EUCAST (P = .69) breakpoints. These results highlight the potential importance of anaerobic antimicrobial susceptibility testing using appropriate MIC breakpoints to improve clinical outcomes.
Finally, we included all clinically significant factors from univariate analysis, including TZP monotherapy as defined by IDSA guidelines alone, in multivariate logistic regression analysis (Table 6 ). Multivariate analysis indicated that the use of empiric TZP monotherapy and ICU stay remained statistically significant (OR, 4.4 and 6.2, respectively). The significance of TZP monotherapy on multivariate analysis suggests careful consideration of empiric antimicrobial guidelines in select cases associated with invasive E. lenta infections, such as perforated appendicitis, may be warranted. 
DISCUSSION
Here, we present the largest population-based study of invasive E. lenta infections and antibiotic susceptibility testing published to date, including107 infections and including 95 BSI. We show a strong association with gastrointestinal infections consistent with the known colonization site of the organism, indicating that E. lenta is the second most common anaerobic infection after B. fragilis. Eggerthella lenta BSIs occurred most commonly in older people, with multiple comorbidities based on Charlson comorbidity score, including diabetes mellitus and solid organ malignancies, which is similar to what has been shown in previous reports [9] [10] [11] [12] . Importantly, our analysis indicates that high TZP MICs are associated with significantly increased mortality when TZP monotherapy is used for empiric management of E. lenta BSIs and reflects the importance of appropriate empiric antimicrobial treatment guidelines and MIC breakpoints for anaerobes.
Eggerthella lenta infections were associated with high morbidity and mortality, especially for non-BSIs. The duration of antibiotics, ICU admission, and mortality was largely similar between our study and previous reported series [9, 12] . Notable exceptions were longer median duration of antibiotic therapy for BSIs of 21.5 days in Gardiner et al's case series [12] compared to 12 days in our study. These findings highlight the clinical importance of E. lenta-associated infections and suggests that mismanagement could be associated with increased costs and poor patient outcomes.
Based on limited reports of antimicrobial susceptibility for E. lenta [10, 12, 15, [27] [28] [29] , there is significant variability in reported resistance patterns, which is likely due to use of different testing methods (ie, agar dilution method and gradient strip methods) [30] . Although no specific interpretive criteria are available for MICs for E. lenta, there is a substantial discrepancy between those established for gram-positive anaerobes by the EUCAST and those for anaerobes by CLSI, in particular, with respect to TZP. This leads to a large and potentially clinically important discrepancy because EUCAST would report only 6% of our isolates as susceptible compared to 80% according to CLSI M100-S21 (2011). For 2018, CLSI has reduced the breakpoint for TZP intermediate from 64 μg/mL to 32 μg/mL, which better reflects clinical outcomes in our study but likely splits the population distribution and therefore may not be an ideal breakpoint for E. lenta [31] . Consistently increased TZP MICs have been found among E. lenta isolates in multiple studies [15, 28, 29, 32] , raising the concern about TZP's clinical efficacy [15] . Thus, our findings highlight growing concerns of anaerobic antimicrobial resistance [33, 34] and the need for clinical microbiology laboratories to perform routine antimicrobial susceptibility testing on isolates recovered from severe invasive anaerobic infections [35] .
Our results further show that the use of empiric TZP is an independent risk factor for mortality. Venugopal et al [9] also documented that 42.9% (3/7) of patients who died had received empiric TZP monotherapy in comparison to 25% (4/16) who survived. Our findings provide heightened concern for the use of TZP as empiric therapy in E. lenta bacteremia in our healthcare jurisdiction given the high TZP MICs of this pathogen. TZP is a commonly used antibiotic in our 4 tertiary-care centers with more than 1500 beds. This is due to its broad spectrum of activity and the lack of availability in Canada of effective carbapenem-sparing alternatives such as parenteral ampicillinsulbactam or amoxicillin-clavulanate. Based on consistently low MICs for metronidazole among E. lenta isolates in our region and elsewhere [10, 12, 16, 28, 36, 37] , the addition of metronidazole to TZP as empiric therapy may be beneficial for the management of infections where E. lenta may be implicated.
Limitations of our study include the retrospective design and the fact that the number of cases was underpowered to demonstrate multiple risk factors associated with mortality on the multivariate analysis. However, our study is the largest population-based study of Eggerthella infections, primarily BSIs published to date. We provide further evidence that E. lenta infections are associated with gastrointestinal infections, particularly perforated appendicitis, and uniquely that the use of TZP monotherapy is a major risk factor for mortality in these infections, possibly owing to high MICs to TZP. Larger prospective studies are needed to confirm our results and to determine appropriate antibiotic management, along with review and agreement of global breakpoints that correlate with clinical outcomes. More readily available identification methods such as MALDI-TOF and increasingly complex patients due to an aging population will likely make diagnosis of E. lenta infections more common and the distinctions between anaerobic susceptibility patterns more relevant in the future.
Notes
